Philip Morris International (PMI), the world’s largest tobacco company, has deepened its involvement in the cannabis sector.
Through its subsidiary, Vectura Fertin Pharma (VFP), PMI announced a partnership with Avicanna Inc., a Canadian biopharmaceutical company specializing in cannabinoid-based products. The collaboration, highlighted in a recent press release, focuses on advancing medical cannabis research and improving patient accessibility in Canada.
“Avicanna and Vectura Fertin Pharma are collaborating to establish a joint Scientific and Medical Affairs Committee focused on improving the understanding of medical cannabis access and applications in Canada”, states the release. “This committee will work closely with Canadian healthcare professionals to facilitate research studies and deliver evidence-based educational resources.”
The collaboration “will prioritize engagement with the Canadian medical community, patients, patient advocacy groups, and insurers to gain insights into the challenges associated with accessing medical cannabis.” Additionally, the collaboration “will leverage Avicanna’s medical cannabis platform, including Mymedi.ca with the aim of improving access and patient support.”
The collaboration is expected to pave the way for a deeper relationship between PMI and Avicanna.
